$350.16-16.54 (-4.51%)
Intuitive Surgical, Inc.
Intuitive Surgical, Inc. in the Healthcare sector is trading at $350.16 with a market capitalization of $141.3B. Wall Street consensus targets $478.01 (30 analysts), implying a +36.5% move over the next 12 months. The stock is currently near its 52-week low of $328.57, remaining 24.3% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.89B↑ | $2.77B↓ | $2.87B↑ | $2.51B↑ | $2.44B |
| Gross Profit | $1.96B↑ | $1.83B↓ | $1.90B↑ | $1.66B↑ | $1.62B |
| Operating Income | $971.90M↑ | $855.30M↓ | $864.30M↑ | $759.70M↑ | $743.40M |
| Net Income | $818.10M↓ | $821.50M↑ | $794.80M↑ | $704.40M↑ | $658.40M |
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Sur...

Intuitive Surgical's Ion platform is gaining momentum, with rising procedures, a larger installed base and global expansion fueling a second growth engine.

Sands Capital, an investment management company, released its second-quarter 2026 investor letter for “Sands Capital Global Growth Fund”. The letter can be downloaded here. Global Growth seeks the best growth businesses worldwide, leveraging a research team that explores both developed and emerging markets for sustainable competitive advantages. In the quarter, global equities rebounded strongly, driven […]

Intuitive Surgical's flywheel isn't selling new surgical robots, its selling parts and services to support the ones it has already sold.

You might regret ignoring these companies at current levels.

Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder from a cyclical recovery story.
Academic risk and quality models computed from ISRG's own filings and price history, not from analyst opinion.
Strong on 8 of 9 fundamental-health tests covering profitability, leverage and operating efficiency.
Altman Z above the 2.99 safe threshold, so the model puts bankruptcy risk in its lowest band.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
Hidden Markov model fitted to two years of returns, separating bull, bear and sideways states by their own drift and volatility.
GARCH(1,1) 30-day annualised forecast, above the current 30.1% reading.
Fama-French 5-factor market beta. The five factors explain 19% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-09-08.